Effects of preterm birth on HIV acquisition risk and antiretroviral prophylaxis safety in HIV-exposed infants in Botswana (PERHAPS)
One of the success stories of the Botswana HIV treatment and prevention program lies in the countries prevention of mother-to-child transmission of HIV program (PMTCT). Currently, over 95% of pregnant women living with HIV are accessing antiretrovirals (ARV) resulting in a mother-to-child (MTCT) transmission rate of <2%, one of the lowest rates in Sub-Saharan Africa. This welcomed achievement, however, means that an increasing number of infants are now exposed to ARVs in utero, potentially contributing to increased preterm birth (PTB) in these population. PTB (birth < 37 weeks gestational age), among HIV-exposed infants in Botswana is approximately 21% in comparison to 13% among HIV-unexposed infants.
Despite the reduced MTCT among HIV-exposed infants, we do not know if the timing or rate of HIV-acquisition for infants born preterm differs from infants born on or after 37 weeks gestational age. In our own work in an early infant treatment study underway in Botswana, which enrolls infants who test HIV positive at birth and are born ≥ 35 weeks gestational age for ART initiation within 7 days of birth, 33.3% of the infants enrolled in that study were born between 35-36 weeks gestational age, a prevalence that exceeds the background preterm birth rate of 21% for infants born to HIV-infected women, suggesting that preterm HIV-exposed infants may be at higher risk for in-utero HIV acquisition. An alternate explanation is that HIV infection may lead to PTB, but this potential for reverse causality has also not been explored by comparing the gestational ages of in utero and intrapartum events.
Also, Botswana PMTCT guidelines currently recommend a triple ARV prophylaxis strategy in the first 4 – 6 weeks of life for HIV-exposed infants deemed to be at “high risk” of HIV-acquisition. In these guidelines, PTB is not recognized as a “high risk” characteristic, in and of itself. Hence in Botswana, preterm HIV-exposed infants, lacking any other risk factor, receive a low-risk HIV prophylactic regimen of single-dose nevirapine within 72 hours of birth and twice daily dosing of Zidovudine for the first 28-30 days of life.
The PERHAPS study was therefore designed to evaluate and explore the relationship that might exist between PTB and
a) mother to child HIV transmission (MTCT)
b) antiretroviral prophylaxis toxicity, in Botswana.
Specifically, the study aims to be able to
- describe the prevalence and timing (in-utero versus peripartum) of MTCT in HIV exposed infants delivered preterm vs those delivered at term in the setting of ART.
- assess the hematologic safety of ARV prophylaxis among HIV-exposed infants born preterm in the first month of life, evaluating for anaemia and/or neutropenia
Funded by the European and Developing Countries Clinical Trials Partnership (EDCTP – TMA2017CDF-1906), researchers at BHP led by Dr Gbolahan Ajibola, will try to provide answers to the research questions raised. The project which started November 2018, will last for 18 months.
Findings from this study will quantify the extent to which PTB confers an increased risk of mother to child transmission of HIV (MTCT) as well as provide information on the efficacy and safety of prophylactic ARV regimens in preterm infants, potentially informing public policy relative to testing and prophylaxis strategies for preterm HIV-exposed infants.